The outcomes from large genome-wide association studies and the modes of action together with the efficacy of existing immunotherapies, point toward circulating and CSF-homing CD4+ T cells (as well as B cells) as central players in the disease process of MS [63]. This evidence concerns the gene CD4 and myeloid sarcoma.